SynthesisFrontiers in endocrinology2025
Risk prediction model for cervical lymph node metastasis of papillary thyroid microcarcinoma: a systematic review and meta-analysis.
Synthesis in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The Regulatory Role and Mechanism of Myoferlin in Mitophagy During Papillary Thyroid Carcinogenesis.The Kaohsiung journal of medical sciences · 2026Article
- Predicting central lymph node metastasis in papillary thyroid microcarcinoma: a study of ultrasound and clinical features.Frontiers in endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: A growing number of risk prediction models for cervical lymph node metastasis (CLNM) in papillary thyroid microcarcinoma (PTMC) have been developed, but their performance and methodological rigor remain unclear. This study systematically reviews these models to evaluate their predictive performance and critically appraise their risk of bias. Methods: We conducted a systematic search of seven databases up to July 29, 2025. The methodological quality of the included studies was assessed using PROBAST. Model performance, measured by the area under the curve (AUC), was pooled using a random-effects meta-analysis. Results: A total of 15 studies, comprising 24 predictive models, were included. The pooled AUC was 0.794 (95% CI: 0.769-0.820), but with substantial heterogeneity ( Conclusion: Although existing CLNM prediction models for PTMC show moderate to good discrimination on average, their clinical utility is severely limited by widespread methodological weaknesses and a high risk of bias. The current evidence is not robust enough to recommend any specific model for routine clinical use, and future research must prioritize methodological rigor and independent external validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.